Alto Neuroscience Announces Director Changes

Ticker: ANRO · Form: 8-K · Filed: Jul 8, 2025 · CIK: 1999480

Alto Neuroscience, Inc. 8-K Filing Summary
FieldDetail
CompanyAlto Neuroscience, Inc. (ANRO)
Form Type8-K
Filed DateJul 8, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: board-changes, officer-compensation, director-appointment, director-departure

TL;DR

Alto Neuroscience board shake-up: Dr. Kupfer out, Dr. Liebowitz in.

AI Summary

Alto Neuroscience, Inc. announced on July 3, 2025, the departure of Director Dr. David Kupfer and the appointment of Dr. Michael R. Liebowitz as a new director. The company also reported on compensatory arrangements for certain officers.

Why It Matters

Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — The filing primarily concerns routine board and officer changes, with no immediate financial or operational risks indicated.

Key Players & Entities

  • Alto Neuroscience, Inc. (company) — Registrant
  • Dr. David Kupfer (person) — Departing Director
  • Dr. Michael R. Liebowitz (person) — Appointed Director
  • July 3, 2025 (date) — Date of earliest event reported

FAQ

Who is Dr. David Kupfer and why did he depart from the board?

Dr. David Kupfer was a Director of Alto Neuroscience, Inc. The filing states his departure but does not provide a reason.

What is Dr. Michael R. Liebowitz's background and role on the board?

Dr. Michael R. Liebowitz has been appointed as a new director. Specific details about his background or committee assignments are not provided in this filing.

What specific compensatory arrangements were discussed for officers?

The filing indicates that compensatory arrangements of certain officers were a subject of this report, but the specific details of these arrangements are not elaborated upon in the provided text.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on July 3, 2025.

What is Alto Neuroscience, Inc.'s principal executive office address?

Alto Neuroscience, Inc.'s principal executive offices are located at 650 Castro St, Suite 450, Mountain View, CA 94041.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 8, 2025 by Dr. David Kupfer regarding Alto Neuroscience, Inc. (ANRO).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.